June 27, 2022
1 min watch
Save
VIDEO: Androgen deprivation therapy shows positive outcomes in metastatic prostate cancer
In this video, Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic, discusses the effective of androgen deprivation therapy on metastatic hormone-sensitive prostate cancer.
Sharifi said that the study he presented at ASCO Annual Meeting found that androgen deprivation therapy does lead to positive outcomes in both groups receiving slow and fast androgen synthesizers, while also providing hypothesis-generating data on possible side effects.
“This is something I think we need to consider, but also requires further study,” Sharifi said.
Reference:
- Sharifi N. The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Sharifi reports consulting for Roivant Sciences and receiving research funding from Astellas Pharma and Bristol Myers Squibb Foundation.
Read more about